Precipio Inc (PRPO)
NASDAQ:PRPO
Want to see PRPO full AI Analyst Report?
PRPO Stock Chart & Stats
$23.09
$0.30(5.08%)
At close: 4:00 PM EST
$23.09
$0.30(5.08%)
Day’s Range― - ―
52-Week Range$5.94 - $33.63
Previous CloseN/A
Volume11.00
Average Volume (3M)19.92K
Market Cap
$53.47M
Enterprise Value$51.09M
Total Cash (Recent Filing)$6.04M
Total Debt (Recent Filing)$3.65M
Price to Earnings (P/E)17.5
Beta0.69
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding1,783,682
10 Day Avg. Volume16,445
30 Day Avg. Volume19,918
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)2.53
Price to Sales (P/S)1.53
P/FCF Ratio102.74
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue2.12
Enterprise Value/Gross Profit4.77
Enterprise Value/Ebitda34.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.4
Revenue Forecast (FY)$80.26M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthPrecipio delivered durable top-line expansion in 2025, driven by Pathology Services and specialized testing. A 30% revenue gain reflects growing clinician adoption and recurring test volume, creating a stable demand base and room for operating leverage as lab capacity is underutilized.
Positive Cash Flow InflectionThe shift to positive operating cash flow and repayment of a material loan materially reduces near-term refinancing risk, improves financial flexibility and funds reinvestment. This cash generation milestone supports sustainable operations and targeted reinvestment into product scaling.
Strengthened Commercial & Clinical CredibilityInvesting in an experienced commercial team and achieving academic validation increases the firm's ability to accelerate product adoption and navigate multi-step lab onboarding. Strong clinical credibility and dedicated sales capacity are durable drivers for sustained market penetration.
Bears Say
Profitability Durability ConcernsDespite improved net results, multi-year negative EBIT/EBITDA and anomalous zero gross/operating profit entries for 2025 undermine confidence in earnings quality. If structural costs or product margins revert, the company may struggle to consistently convert revenue growth into sustainable operating profits.
Products Revenue & Margin VolatilityThe Products division exhibits inconsistent revenue ramps and extreme margin swings driven by one-time production timing and customer operational interruptions. Such volatility makes long-term revenue predictability and margin modeling difficult, limiting durable contribution to consolidated profits.
Shrinking Asset Base & Modest Cash CushionA declining asset base and historically negative ROE signal past value erosion; 2025 reporting gaps limit transparency. Although cash flow turned positive, coverage is modest relative to business needs, leaving limited cushion for execution setbacks or investment cycles without external funding.
Precipio News
PRPO FAQ
What was Precipio Inc’s price range in the past 12 months?
Precipio Inc lowest stock price was $5.94 and its highest was $33.63 in the past 12 months.
What is Precipio Inc’s market cap?
Precipio Inc’s market cap is $53.47M.
When is Precipio Inc’s upcoming earnings report date?
Precipio Inc’s upcoming earnings report date is May 20, 2026 which is in 13 days.
How were Precipio Inc’s earnings last quarter?
Precipio Inc released its earnings results on Apr 06, 2026. The company reported $0.295 earnings per share for the quarter, beating the consensus estimate of N/A by $0.295.
Is Precipio Inc overvalued?
According to Wall Street analysts Precipio Inc’s price is currently Overvalued.
Does Precipio Inc pay dividends?
Precipio Inc does not currently pay dividends.
What is Precipio Inc’s EPS estimate?
Precipio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Precipio Inc have?
Precipio Inc has 1,783,682 shares outstanding.
What happened to Precipio Inc’s price movement after its last earnings report?
Precipio Inc reported an EPS of $0.295 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.283%.
Which hedge fund is a major shareholder of Precipio Inc?
Currently, no hedge funds are holding shares in PRPO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precipio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.84%
12-Months-Change
Fundamentals
Return on Equity
-2.78%
Trailing 12-Months
Asset Growth
25.42%
Trailing 12-Months
Company Description
Precipio Inc
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
PRPO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicates a generally positive trajectory: the company reached a key inflection to positive cash flow, delivered 30% revenue growth to $24M, improved overall gross margin from 41% to 45%, strengthened the commercial organization, and demonstrated product manufacturing scalability and clinical validation. Key challenges remain in the Products division—revenue growth was muted by customer operational interruptions, earlier under-resourced commercial coverage, onboarding timing and margin volatility driven by one-time production effects. Management presented concrete mitigations (new hires, backup lab arrangements, distributor strategy) and a clear growth focus for 2026, so the balance of developments is favorable but with identifiable execution risks to monitor.View all PRPO earnings summariesTechnical Analysis
Trinity Biotech
―
DarioHealth
―
BioNano Genomics
―
Intelligent Bio Solutions
―
bioAffinity Technologies, Inc.
―
Ownership Overview
11.08% Insiders
1.76% Mutual Funds
0.53% Other Institutional Investors
85.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---